by Annie De Groot | Feb 26, 2019 | Events
2nd Antigen-Specific Immune Tolerance Drug Development Summit Tuesday, March 26th – Thursday, March 28th, 2019 Wyndham Boston Beacon Hill 5 Blossom Street Boston, Massachusetts 02114 USA Join Dr. Annie De Groot, CEO/CSO EpiVax, at the 2nd Antigen-Specific Immune...
by Sarah Moniz | May 18, 2018 | News
PROVIDENCE, R.I., May 18, 2018 /PRNewswire/ — The National Institutes of Health (NIH) has awarded EpiVax, Inc. (“EpiVax”), experts in the field of immunogenicity risk assessment, a $324,980 Small Business Innovation Research (SBIR) grant. The funding will enable...
